1. 1703PIncidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). (23rd October 2018) Authors: von Moos, R; Hawle, H; Hayoz, S; Cathomas, R; Müller, A; Schmid, S; Pagani, O; Wehrhahn, T; Rauch, D; Anchisi, S; Hermanns, T; Fehr, M; Stoll, S; Bützberger, P; Zweifel, M; Huber, U; Fuhrer, A C; Schär, C; Gillessen, S; Templeton, A J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗